How EMPAVELI can help | HEMOGLOBIN
Increased hemoglobin with EMPAVELI
Superior improvements in hemoglobin (Hb) in people who had previously received a C5i: results at Week 16 Primary goal in the PEGASUS study: to explore whether EMPAVELI was better at improving Hb levels than a C5i (eculizumab) in people living with paroxysmal nocturnal hemoglobinuria (PNH)
Peg is an adult with PNH taking EMPAVELI.
In people who had previously received a C5i (PEGASUS)
Hb improvement was maintained through the 48-week study
People taking EMPAVELI had a 2.37 g/dL Hb INCREASE
SUPERIOR Hb DIFFERENCE of 3.84 g/dL with EMPAVELI compared to eculizumab ( P <0.0001)
Average change in Hb levels from beginning to Week 48
People taking eculizumab had a 1.47 g/dL Hb DECREASE
View graph of Hb improvement over 16 weeks
IMPORTANT SAFETY INFORMATION (cont’d) Who should NOT take EMPAVELI? Do not take EMPAVELI if you: are allergic to pegcetacoplan or any of the ingredients in EMPAVELI.
have not been vaccinated against Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B, unless your healthcare provider decides that urgent treatment with EMPAVELI is needed. have a serious infection caused by the bacteria above.
C5i=C5 inhibitor; EMP=EMPAVELI; OLP=open-label period; RCP=randomized control period; SE=standard error.
Please see full Important Safety Information, including Boxed WARNING regarding risk of serious infections, on pages 38-39, and the full Prescribing Information and Medication Guide.
10
11
Made with FlippingBook flipbook maker